|Videos|April 26, 2023
EDS Evaluation
Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).
Advertisement
Episodes in this series
Advertisement
Related to this article
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026
4
New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP
5